Laureate Pharma, Inc. has entered into a contract manufacturing agreement with Alopexx Pharmaceuticals to produce Alopexx’s mAb F598 antibody under cGMP conditions. This antibody will be used in clinical trials and later for commercial production for the treatment and prevention of Staphylococcus aureus infections.       “We are pleased that Alopexx chose Laureate Pharma as their manufacturing partner,” said Robert J. Broeze, Ph. D., president and chief executive officer of ...